Legend Biotech Corporation (LEGN) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $35.35: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is... Read more
Sell if holding. Engine safety override at $35.35: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Score 6.0/10, moderate confidence.
Passes 7/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 56d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent developments
updated 2026-06-15Recent Developments — Legend Biotech Corporation
Latest news
- NEWS Reported Sunday, Legend Biotech's LB2501 In Vivo CD19/CD20 Dual-Targeting CAR-T Achieves 100% ORR And 83.3% CR Rate At D — benzinga Jun 15, 2026 positive
- NEWS UBS Maintains Buy on Legend Biotech, Raises Price Target to $49 — benzinga Jun 3, 2026 neutral
- NEWS 10 Health Care Stocks Whale Activity In Today's Session — benzinga Jun 3, 2026 neutral
- NEWS Palo Alto Networks To Rally Nearly 70%? Here Are 10 Notable Analyst Calls From Wednesday — benzinga Jun 3, 2026 positive
- NEWS HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $65 — benzinga Jun 3, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $35.35: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10 and A.R:R 3.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 62, MACD bullish. Prior stop was $32.89. Score 6.0/10, moderate confidence.
Take-profit target: $51.84 (+46.6% upside). Prior stop was $32.89. Stop-loss: $32.89.
Quality below floor (2.0 < 4.0).
Legend Biotech Corporation trades at a P/E of N/A (forward 26.9). TrendMatrix value score: 7.2/10. Verdict: Sell.
23 analysts cover LEGN with a consensus score of 4.2/5. Average price target: $58.
What does Legend Biotech Corporation do?Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops,...
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.